setd2

EZM0414 TFA (SETD2-IN-1 TFA) 是一种具有口服活性和选择性的人类组蛋白甲基转移酶 SETD2 抑制剂，具有抗癌和抗增殖作用，可用于研究白血病和免疫功能异常。

EZM0414 是一种有效、选择性、口服生物利用度高的SETD2抑制剂，在 SETD2 生化分析中，IC50值为18 nM；在细胞分析中，IC50值为34 nM。EZM0414可用于复发或难治性多发性骨髓瘤和弥漫性大 B 细胞淋巴瘤的研究。

MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2 WHSC1) .

AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo[1]. AS-99 TFA is tested against a panel of 20 histone methyltransferases, including NSD1, NSD2, NSD3, and SETD2. NO significant inhibition is observed at 50 μM of AS-99 TFA on any of the tested histone methyltransferases, indicating over 100-fold selectivity towards ASH1L[1].AS-99 TFA shows effect on the growth of the MLL leukemia cells (MV4;11, MOLM13, KOPN8, RS4;11) with the GI50 values ranging from 1.8 μM to 3.6 μM[1].AS-99 (1-8 μM; 7 days) TFA also induces apoptosis in the MLL leukemia cells, but not in the K562 cells, as assessed by the quantification of the Annexin V positive cells[1].AS-99 TFA suppresses MLL fusion driven transcriptional programs[1]. AS-99 (30 mg kg; i.p.; q.d., treated for 14 consecutive days) TFA reduces leukemia burden in mice[1].AS-99 TFA is used for in vivo studies in mice, which reveals favorable exposure in plasma upon i.v. and i.p. administration (AUC = 9701 hr* ng mL and 10,699 hr* ng mL, respectively), suitable half-life (~5-6 h) and Cmax >10 μM[1]. [1]. David S. Rogawski, Jing Deng, Hao Li, Tomasz Cierpicki, Jolanta Grembecka, et al. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 May 14;12(1):2792.

EPZ-719 is a highly selective and potent inhibitor of SETD2, a novel compound known for its ability to inhibit the enzymatic activity of SETD2 (IC50 = 0.005 μM). This compound displays a remarkable selectivity over other histone methyltransferases, making it a promising candidate for targeted therapeutic applications in the field of epigenetic research.